Table 3.

Secondary outcomes

Parameter	Intervention Arm	Control Arm	P Value
eGFR
At 1 mo	47 (35–62)	50 (38–61)	0.45
At 3 mo	48 (37–64)	52 (40–61)	0.92
At 6 mo	53 (39–68)	53 (39–63)	0.88
At 1 yr	53 (43–71)	56 (44–68)	0.83
Proteinuria at 1 yr
Protein/creatinine ratio, mg/mmol	11 (6–19)	11 (6–19)	0.82
Albumin/creatinine ratio, mg/mmol	3.0 (1.0–7.0)	2.4 (0.9–6.9)	0.65
BKPyV DNAemia	29 (24%)	26 (21%)	0.65
BKPyV peak DNAemia, copies/ml	20,200 (9000–90,450)	38,850 (6703–192,100)	0.73
Cytomegalovirus infection
No CMV replication	90 (75%)	88 (73%)
Asymptomatic CMV infection	20 (17%)	20 (16%)	0.80
CMV disease (CMV syndrome)	3 (2%)	6 (5%)
CMV disease (tissue invasive)	7 (6%)	7 (6%)
Number of other infection episodes
Including lower UTIs (0/1/≥2)	49%/33%/18%	46%/23%/31%	0.06
Excluding lower UTIs (0/1/≥2)	58%/33%/9%	52%/27%/21%	0.04
Metabolism
Body mass index at 1 yr	25.7 (23.1–29.4)	26.0 (23.3–30.1)	0.77
Change of body mass index from pretransplant	+0.2 (−1.0 to +1.5)	+0.6 (−0.7 to +2.1)	0.25
New-onset diabetes after transplant	9 (8%)	11 (9%)	0.82
Chronic lesions in allograft biopsies
ci + ct score in implantation biopsy (n=210)	0.83±0.75	0.94±0.76	0.28
ci + ct score in 1-yr surveillance biopsy (n=201)	1.99±1.31	1.91±1.28	0.66
Delta ci + ct score (n=173)	1.21±1.34	1.17±1.44	0.85

Data are given as count (percentage), median (interquartile range), or mean±SD as appropriate. Comparisons were performed by the Fisher exact test, Wilcoxon test, or t test as appropriate. BKPyV, BK polyomavirus; CMV, cytomegalovirus; UTI, urinary tract infection.